Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.95 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.95 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.95 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.95 |
| ▸ | CES2 | O00748 | 1/20 | 0.67 |
| ▸ | CES1 | P23141 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Picolinic Acid SCHEMBL134791 | 1.00 | LMNA (0.95) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL1462616 | 1.00 | LMNA (0.95) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL664133 | 1.00 | LMNA (0.95) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL29480469 | 1.00 | LMNA (0.95) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL29360523 | 1.00 | LMNA (0.95) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL27680667 | 0.98 | LMNA (0.91) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL28174521 | 0.98 | LMNA (0.91) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL6285136 | 0.98 | LMNA (0.91) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL27695178 | 0.98 | LMNA (0.91) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL674837 | 0.98 | LMNA (1.00) | LMNAL3MBTL1NAPRTP4HTMCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148748-A1 | CHROMIUM CONTAINING COMPOSITIONS FOR IMPROVING HEALTH AND FITNESS | NUTRITION21 LLC (US) | 2024-05-09 | — | — | US | disclosed |
| US-11865121-B2 | Chromium containing compositions for improving health and fitness | Nutrition21, LLC (US) | 2024-01-09 | — | — | US | disclosed |
| US-11857553-B2 | Chromium containing compositions for improving health and fitness | Nutrition21, LLC (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3050568-B1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | JDS THERAPEUTICS LLC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20190314510-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT | 2019-10-17 | — | — | US | disclosed |
| US-20190216821-A1 | Chromium Containing Compositions for Improving Health and Fitness | CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT | 2019-07-18 | — | — | US | disclosed |
| US-10245325-B2 | Methods and compositions for the sustained release of chromium | JDS THERAPEUTICS, LLC (US) | 2019-04-02 | — | — | US | disclosed |
| EP-3413900-A1 | CHROMIUM CONTAINING COMPOSITIONS FOR IMPROVING HEALTH AND FITNESS | Nutrition 21, LLC (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20170304360-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT | 2017-10-26 | — | — | US | disclosed |
| US-20170239267-A1 | CHROMIUM CONTAINING COMPOSITIONS FOR IMPROVING HEALTH AND FITNESS | CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT | 2017-08-24 | — | — | US | disclosed |
| EP-3050568-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | Nutrition 21, Inc. (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2134351-B1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | NUTRITION 21 INC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-20150320874-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT | 2015-11-12 | — | — | US | disclosed |
| US-20150320796-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT | 2015-11-12 | — | — | US | disclosed |
| US-9119835-B2 | Methods and compositions for the sustained release of chromium | JDS Therapeautics, LLC (US) | 2015-09-01 | — | — | US | disclosed |
| US-20120128794-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | NUTRITION 21, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-8062677-B2 | Methods and compositions for the sustained release of chromium | NUTRITION 21, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2134351-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | Nutrition 21, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090155384-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT | 2009-06-18 | — | — | US | disclosed |
| WO-2008112706-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | NUTRITION 21, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155384-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | LDLR, TNNC1, LIPA | LMNA 229/4885L3MBTL1 4113/4885NAPRT 3844/4885 |
| US-20120128794-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | LDLR, TNNC1, LIPA | LMNA 229/4885L3MBTL1 4113/4885NAPRT 3844/4885 |
| US-20150320874-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | LDLR, TNNC1, LIPA | LMNA 229/4885L3MBTL1 4113/4885NAPRT 3844/4885 |
| US-20190216821-A1 | Chromium Containing Compositions for Improving Health and Fitness | GYS1, MUSK, PYGM | LMNA 1223/4885L3MBTL1 3744/4885NAPRT 4176/4885 |
| US-20240148748-A1 | CHROMIUM CONTAINING COMPOSITIONS FOR IMPROVING HEALTH AND FITNESS | GYS1, MUSK, PYGM | LMNA 1223/4885L3MBTL1 3744/4885NAPRT 4176/4885 |
| US-20190314510-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | LDLR, TNNC1, LIPA | LMNA 229/4885L3MBTL1 4113/4885NAPRT 3844/4885 |
| US-11865121-B2 | Chromium containing compositions for improving health and fitness | GYS1, MUSK, PYGM | LMNA 1223/4885L3MBTL1 3744/4885NAPRT 4176/4885 |
| US-10245325-B2 | Methods and compositions for the sustained release of chromium | LDLR, TNNC1, LIPA | LMNA 229/4885L3MBTL1 4113/4885NAPRT 3844/4885 |
| US-20170239267-A1 | CHROMIUM CONTAINING COMPOSITIONS FOR IMPROVING HEALTH AND FITNESS | GYS1, MUSK, PYGM | LMNA 1223/4885L3MBTL1 3744/4885NAPRT 4176/4885 |
| US-20170304360-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | LDLR, TNNC1, LIPA | LMNA 229/4885L3MBTL1 4113/4885NAPRT 3844/4885 |
| US-11857553-B2 | Chromium containing compositions for improving health and fitness | GYS1, MUSK, PYGM | LMNA 1223/4885L3MBTL1 3744/4885NAPRT 4176/4885 |
| US-20150320796-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | LDLR, TNNC1, LIPA | LMNA 229/4885L3MBTL1 4113/4885NAPRT 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.